Perspectum

Perspectum is a global medical technology company that delivers advanced quantitative imaging solutions designed to help doctors make better clinical decisions, personalize patient care, and achieve improved outcomes. By extracting actionable biomarkers from medical imaging in an intuitive and streamlined way, Perspectum moves beyond conventional one-dimensional diagnostics to provide a fuller, more comprehensive picture of patient health — enabling faster diagnoses and more precise treatment strategies.

Founded and led by renowned physicians and scientists — including co-founder Sir Michael Brady, recently elected as an International Member of the National Academy of Engineering — Perspectum combines proven scientific leadership with a patient-first philosophy. The company serves patients, healthcare professionals, and researchers across metabolic diseases, liver disease, cancer, diabetes, and other chronic conditions.

Core Technology and Imaging Solutions

• Proprietary quantitative imaging technology that extracts biomarkers from MRI in a safe, fast, and non-invasive manner
• Patented methods that deliver multi-dimensional, actionable insights compared to conventional black-and-white diagnostics
• Corrected T1 (cT1), a proprietary biomarker identified as the most appropriate tool for diagnosis and monitoring in the context of metabolic liver disease treatments such as resmetirom
• Solutions designed to help clinicians understand complex imaging data and deliver precision care at scale

Who Perspectum Serves

• Patients: Perspectum believes every patient and every case is unique; its solutions enable healthcare providers to tailor precision medicine to individual needs, supporting a kinder and more personalized healthcare system
• Healthcare Professionals: Non-invasive technology provides actionable information from imaging in a streamlined way, supporting faster and more accurate diagnoses and better patient outcomes
• Researchers: Perspectum collaborates with world-leading experts to accelerate research into metabolic diseases, cancer, diabetes, and other chronic conditions

Key Focus Areas and Disease Specializations

• Metabolic disease and metabolic liver disease, including monitoring of emerging pharmacological treatments
• Liver disease assessment and quantification
• Oncology and cancer research
• Diabetes and other chronic diseases
• Multi-organ and musculoskeletal imaging applications

Partnerships, Reach, and Notable Developments

• Strategic partnership with Avant Santé to strengthen quantitative imaging for metabolic and liver research across Mexico and Latin America
• National diagnostics partnership with InHealth to expand access to advanced MRI across the UK and increase capacity at the Oxford Clinical Diagnostic Centre (CDC)
• Economic modeling published in 2025 supports the use of Perspectum's cT1 biomarker as a cost-effective tool for widespread adoption in the United States in the context of resmetirom treatment for liver disease
• Active presence at major medical conferences, including the AACE Annual Meeting
• Leadership transition in early 2026, with Dr. Rexford Newbould appointed as Interim Chief Executive Officer

Perspectum continues to expand its global footprint and clinical partnerships, driving the adoption of quantitative imaging as a standard of care in precision medicine and positioning itself at the forefront of non-invasive diagnostics for metabolic and chronic diseases worldwide.